Virios Therapeutics (NASDAQ:VIRI – Free Report) had its price target boosted by HC Wainwright from $0.20 to $5.00 in a research note issued to investors on Wednesday, Benzinga reports. They currently have a neutral rating on the stock.
Separately, Maxim Group assumed coverage on Virios Therapeutics in a report on Thursday, June 20th. They set a buy rating and a $1.00 price target on the stock.
View Our Latest Analysis on VIRI
Virios Therapeutics Stock Up 32.0 %
Virios Therapeutics (NASDAQ:VIRI – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. During the same period in the prior year, the firm earned ($0.08) EPS. Sell-side analysts anticipate that Virios Therapeutics will post -0.22 earnings per share for the current fiscal year.
About Virios Therapeutics
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Recommended Stories
- Five stocks we like better than Virios Therapeutics
- Stock Market Sectors: What Are They and How Many Are There?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- What Investors Need to Know to Beat the Market
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.